Christian Henry
President and Chief Executive Officer
Replay available
Pacific Biosciences of California, Inc. (PACB) Q2 2025 Earnings Call
Pacific Biosciences of California, Inc. (NASDAQ: PACB) Q2 2025 earnings conference call, held 2025-08-07. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Jim Kowalski
Chief Financial Officer and Chief Operating Officer
David Westenberg
Analyst, Piper Sandler & Co.
Jack Meehan
Analyst, NetFront Research
Kyle Mixon
Analyst, Canaccord Genuity
Doug Schenkel
Analyst, Wolf Research
Subu Nambi
Analyst, Guggenheim Securities
Tyco Peterson
Analyst, Jefferies
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Pacific Biosciences Of California, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.000 -- 00:00:05.340 went to brand new customers, and one third were to LDT diagnostic or 00:00:05.340 -- 00:00:10.940 hospital labs, encouraging signs that Hi-Fi is gaining share in these labs, 00:00:10.940 -- 00:00:14.360 replacing a number of legacy technologies. 00:00:14.360 -- 00:00:18.720 This is especially true in genetic and rare disease testing. 00:00:18.720 -- 00:00:22.500 A few recent examples include Variantix, 00:00:22.500 -- 00:00:27.500 a diagnostics lab based in Boston and a new to PAC Bio customer that is 00:00:27.500 -- 00:00:32.860 seeking to improve key genetic disease assays by using Revio and PacBio 00:00:32.860 -- 00:00:38.540 Hi-Fi sequencing in lieu of legacy sequencing technologies. 00:00:38.640 -- 00:00:43.780 GeneDx also added another Revio to its fleet in the second quarter and plans to incorporate 00:00:43.780 -- 00:00:48.740 our pure target chemistry to further advance key tests. 00:00:48.740 -- 00:00:54.120 Additionally, we placed additional Revio systems into hospital systems in northern Europe 00:00:54.120 -- 00:00:59.260 where Hi-Fi is being used to advance the understanding and improve solve rates 00:00:59.260 -- 00:01:02.660 for rare disease at scale. 00:01:03.180 -- 00:01:07.660 Turning to Vega, the PacBio team has built a robust platform. 00:01:07.660 -- 00:01:11.880 We're extremely pleased with the system's continued momentum and strong performance in 00:01:11.880 -- 00:01:16.900 the field. In the second quarter, nearly 60% of Vega shipments were to 00:01:16.900 -- 00:01:21.980 new PacBio customers. And since launching in very late Q4 last year, 00:01:21.980 -- 00:01:27.600 Vega has brought over 40 new laboratories into the PacBio ecosystem, 00:01:27.600 -- 00:01:32.080 a number we expect to grow into the future....